Compare VTRS & JBHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | JBHT |
|---|---|---|
| Founded | 1961 | 1961 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 19.5B |
| IPO Year | 2019 | 1994 |
| Metric | VTRS | JBHT |
|---|---|---|
| Price | $13.15 | $217.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $13.50 | ★ $201.90 |
| AVG Volume (30 Days) | ★ 8.0M | 807.6K |
| Earning Date | 05-07-2026 | 04-15-2026 |
| Dividend Yield | ★ 3.58% | 0.83% |
| EPS Growth | N/A | ★ 10.07 |
| EPS | N/A | ★ 6.12 |
| Revenue | ★ $14,299,900,000.00 | $7,189,568,000.00 |
| Revenue This Year | $4.45 | $5.27 |
| Revenue Next Year | $1.79 | $6.78 |
| P/E Ratio | ★ N/A | $35.50 |
| Revenue Growth | N/A | ★ 9.67 |
| 52 Week Low | $6.85 | $122.79 |
| 52 Week High | $16.47 | $236.00 |
| Indicator | VTRS | JBHT |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 59.51 |
| Support Level | $12.90 | $216.08 |
| Resistance Level | $13.49 | $235.41 |
| Average True Range (ATR) | 0.35 | 5.68 |
| MACD | 0.02 | 2.06 |
| Stochastic Oscillator | 34.16 | 93.33 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).